Article
JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
Journal of gastroenterology - 1 Jun 2020
Takehara Tetsuo, Chayama Kazuaki, Kurosaki Masayuki, Yatsuhashi Hiroshi, Tanaka Yasuhito, Hiramatsu Naoki, Sakamoto Naoya, Asahina Yasuhiro, Nozaki Akito, Nakano Toshikazu, Hagiwara Yosuke, Shimizu Hiroko, Yoshida Hiroki, Huang Yuhan, Biermer Michael, Vijgen Leen, Hayashi Norio
Abstract excerpt
BACKGROUND: The efficacy, safety, and pharmacokinetics of the combination of three direct-acting antiviral (DAA) agents (adafosbuvir [also known as AL-335], odalasvir, and simeprevir) were investigated in DAA treatment-naïve Japanese patients with genotype (GT)1 or GT2 chronic hepatitis C virus (HCV) infection, with or without compensated cirrhosis. METHODS: In this Phase IIa, open-label, multicenter...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.